| 64.92 Delayed Data As of Mar 21 |  +0.32 / +0.50%Today’s Change | 60.32 Today|||52-Week Range 79.61 | +3.79% Year-to-Date |
| Gilead Sciences (GILD) Gains As Market Dips: What You Should Know Mar 19 / Zacks.com - Paid Partner Content | Is iShares Nasdaq Biotechnology Index Fund a Buy? Mar 11 / MotleyFool.com - Paid Partner Content |
| Better Buy: Amgen vs. Gilead Sciences Mar 17 / MotleyFool.com - Paid Partner Content | 3 Top Biotech Stocks to Buy in March Mar 09 / MotleyFool.com - Paid Partner Content |
| Agenus Wins $7.5M Milestone Payment From Gilead, Stock Up Mar 14 / Zacks.com - Paid Partner Content | Gilead Reports Positive Data on HIV Drugs Biktarvy & Descovy Mar 08 / Zacks.com - Paid Partner Content |
| Gilead Sciences (GILD) Outpaces Stock Market Gains: What You Should Know Mar 13 / Zacks.com - Paid Partner Content |
| Previous close | 64.60 |
| Today’s open | 64.14 |
| Day’s range | 63.00 - 65.02 |
| Volume | 9,069,470 |
| Average volume (3 months) | 7,754,409 |
| Market cap | $83.3B |
| Earnings growth (last year) | +4.62% |
| Earnings growth (this year) | -0.52% |
| Earnings growth (next 5 years) | +1.08% |
| Revenue growth (last year) | -15.00% |
| P/E ratio | 15.6 |
| Price/Sales | 3.68 |
| Price/Book | 3.91 |
| Today’s change | Today’s % change | |
|---|---|---|
| BIIBBiogen | -93.71 | -29.23% |
| AMGNAmgen | +0.77 | +0.40% |
| ILMNIllumina Inc | +3.91 | +1.24% |
| EXASExact Sciences Corp | +1.54 | +1.70% |
| Next reporting date | May 2, 2019 |
| EPS forecast (this quarter) | $1.62 |
| Annual revenue (last year) | $22.2B |
| Annual profit (last year) | $5.5B |
| Net profit margin | 24.56% |
Sector Health Technology |
Industry Biotechnology |
Chairman & Chief Executive Officer Daniel O'Day |
CFO, Principal Accounting Officer & Executive VP Robin L. Washington |
Corporate headquarters Foster City, California |
